# EPU5 – HealthTech Regulation in Tunisia: Insights from FMM × HCI > Source: https://healthcareinnovation.tn/epu5-healthtech-regulation-in-tunisia-insights-from-fmm-x-hci/ > Author: healthcareinnovation.com > Published: 2024-03-02 > Updated: 2026-09-17 How can Tunisia shape a HealthTech regulatory framework that enables innovation while protecting patients? A postgraduate panel co-hosted by the [Faculty of Medicine of Monastir (FMM)](https://www.fmm.rnu.tn/) and [HealthCare Innovation (HCI)](https://healthcareinnovation.tn/) examined gaps, costs, and feasible reforms to accelerate compliant growth in digital health, medtech, and biotech. ## **Context & Participants** Held on 2 March 2024 in the ceremonial auditorium of the [Faculty of Medicine of Monastir (FMM)](https://www.fmm.rnu.tn/), the session brought together 100+ clinicians, researchers, administrators, and students across Monastir, Sousse, Mahdia, and Tunis. ## **Why Regulation Matters for HealthTech** Predictable, risk-based regulation is essential for adoption and market access. The [EU Medical Devices Regulation (MDR 2017/745)](https://health.ec.europa.eu/medical-devices-regulatory-framework/overview_en) sets requirements for CE marking in Europe, while the [U.S. FDA](https://www.fda.gov/medical-devices/overview-center-medical-devices-and-radiological-health-cdrh) oversees market authorization in the United States. Data protection frameworks such as the [GDPR](https://gdpr.eu/) govern privacy and security for digital health. Global public-health bodies like the [WHO](https://www.who.int/publications/i/item/9789240068891) emphasize governance, workforce skills, and interoperability as enablers of safe digital health adoption. https://www.youtube.com/watch?v=xh2NbF5lC-Q #### **Key Challenges Identified** - Regulatory gap on medical devices supervision and safety; need for clearer guidance and timelines. - High CE-marking costs that vary by device class (from tens of thousands to several hundred thousand euros). - Limited local accreditation capacity for testing and conformity assessment, constraining time-to-market. - Small domestic market dynamics (e.g., online payments) and capital controls deterring foreign investment inflows. - Slow promulgation and enforcement, creating uncertainty for innovators and investors. #### **Pragmatic Recommendations for Tunisia** 1) Start with the Target Market & Risk Class: plan the product roadmap against [EU MDR](https://health.ec.europa.eu/medical-devices-regulatory-framework/overview_en) and/or [FDA pathways](https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/how-study-and-market-your-device); define intended use, clinical evaluation needs, and evidence from day one. 2) Build Compliance-by-Design: align early with data protection ([GDPR](https://gdpr.eu/)), cybersecurity hygiene, and quality management (e.g., ISO 13485 contexts). 3) Strengthen Local Testing & Accreditation: create or upgrade labs to support verification/validation and reduce reliance on foreign facilities. 4) Reduce Cost Barriers: deploy earmarked grants or guarantees to co-finance CE marking for startups; explore regional or pan-African schemes. 5) Enable PPP & Clearer Guidance: publish practical playbooks and timelines for pilots in hospitals, with transparent review gates. 6) Think Euro‑Med & Africa Early: design for multi-market compliance and distribution; leverage diaspora expertise and partnerships. 7) Update Legislation with a HealthTech Lens: consider dedicated taskforces and ministerial coordination to keep pace with innovation. #### **Best Practices & Technology Categories** - Categorize innovations by domain: HealthTech, MedTech, BioTech, and Deep Tech; tailor risk and evidence accordingly. - Combine rapid prototyping with staged certification: prototype locally, document evidence, then seek CE/FDA while building brand and partnerships. - Consider setting up abroad (e.g., UK/EU) for investment access while maintaining R&D roots in Tunisia. #### **HCI Resources** Accelerating Innovation in HealthTech → [https://healthcareinnovation.tn/accelerating-innovation-in-healthtech/](https://healthcareinnovation.tn/accelerating-innovation-in-healthtech/) Startup Programs → [https://healthcareinnovation.tn/service/startups/](https://healthcareinnovation.tn/service/startups/) Pharma & Medical Device Regulatory Services → [https://healthcareinnovation.tn/service/pharma-medical-device/](https://healthcareinnovation.tn/service/pharma-medical-device/) Experts Network → [https://healthcareinnovation.tn/experts/](https://healthcareinnovation.tn/experts/) Community Overview → [https://healthcareinnovation.tn/community/](https://healthcareinnovation.tn/community/) #### **External Citations** EU MDR overview — European Commission: [https://health.ec.europa.eu/medical-devices-regulatory-framework/overview_en](https://health.ec.europa.eu/medical-devices-regulatory-framework/overview_en) FDA medical devices — U.S. FDA: [https://www.fda.gov/medical-devices](https://www.fda.gov/medical-devices) GDPR guide — GDPR.eu: [https://gdpr.eu/](https://gdpr.eu/) WHO Global Strategy on Digital Health: [https://www.who.int/publications/i/item/9789240068891](https://www.who.int/publications/i/item/9789240068891) #### **FAQ** Q: What makes CE marking so expensive for startups? A: Costs combine notified body fees, testing, documentation, and clinical evaluation—scaling with device class and complexity. Q: How can Tunisia reduce time-to-compliance? A: Expand accredited testing capacity, publish hospital pilot playbooks, and co-finance certification steps for early-stage innovators. Q: Should founders wait for perfect regulations before building? A: No—prototype and generate evidence while tracking EU/FDA pathways; iterate with hospitals and research labs, then certify. Q: Where can I get support? A: Engage with [HCI’s Startup Programs](https://healthcareinnovation.tn/service/startups/), the [HCI Experts Network](https://healthcareinnovation.tn/experts/), and [HCI Regulatory Services](https://healthcareinnovation.tn/service/pharma-medical-device/).